Nestec S.a.

Ab2 Bio Sa

Institut Curie

Societe Des Produits Nestle S.a.

Eduardo Schiffrin

Florence Rochat

Jalil Benyacoub

Pablo Perez

Roberto Reniero

Ralf Zink

Christoph Cavadini

Dominique Brassart

Anne Donnet-Hughes

Greg Del Val

Thierry Der Weid

Anne Donnet

Virginie Rousseau

Jean-Richard Neeser

Francois-Pierre Martin

Ferdinand Haschke

Alain Servin

Thierry Von Der Weid

Harriet Link

Olivier Mignot

Virginia Rousseau

Guillermo Kociubinski

Viral Brahmbhatt

Carlos Guarner

German Soriano

Ruth Knorr

Denis Breuille

Stephanie Blum-Sperisen

Magali Faure

Fabrizio Arigoni

Marie-Claire Fichot

Lionel Jean Rene Bovetto

Sebastian Amigorena

Michael Affolter

Claudia Roessle

Laurent Favre

Isabelle Bureau-Franz

Marco Enrico Turini

Karl-Josef Huber-Haag

Kevin Burke Miller

Michele Delley

Veronique Jaussan

Yves Guigoz

Olivier Jacques Lantz

Michèle Delley

Mark Alan Schell

Stéphanie Blum

François-Pierre Martin

Denis Breuillé

Stéphanie Blum-Sperisen

Mario Labeta

Mohamed Nabil Bosco

Evelyn Spivey-Krobath

Claude Cavadini

Anthony C Huggett

Stephanie Blum

Sebastian Diego Amigorena

Denis Breuill

The present invention provides means and methods for treating Interleukin 18 (IL-18)-associated diseases and disorders. In particular, the present invention discloses antibodies specific for free IL-18 and IL-18 Binding Protein (IL-18BP) for use in such treatments and for the diagnosis of the diseases and disorders.

IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases

The present invention provides means and methods for treating Interleukin 18 (IL-18)-associated diseases and disorders, in particular, the present invention discloses antibodies specific for free IL-18 and IL-18 Binding Protein (IL-18BP) for use in such treatments and for the diagnosis of the diseases and disorders.

The present invention relates to methods and immunonutritional compositions for preventing or mitigating paralysis of the bone marrow, caused by a tumor or neoplasm, between cycles of and after anti-cancer therapy, thereby attaining a better efficacy of the treatment. More particularly, the present invention relates to methods and immunonutritional compositions that can transiently preventing or moderating, bone marrow paralysis or neutropenia of a subject tumor-induced apoptosis or necrosis or other cell damage such that the innate and adaptive immune functions and normal physiology of the bone marrow are preserved, at least in part, which, in turn, lead to (i) a better tolerance and increased efficacy to treatment; (ii) transient augmentation or enhancement of immunocompetence of the immune cell; and (iii) optimization of the effects of and increase of immunocompetence of the immune cell weakened due to paralysis of the bone marrow, caused by a tumor or neoplasm.

Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumor

A nutritional composition promotes musculoskeletal health in patients with inflammatory bowel disease. The nutritional composition contains casein protein, vitamin D, alpha-linolenic acid, and vitamin K in a ratio of vitamin K1:vitamin K2 between 3:1 to 1:3 and the vitamin K providing between 3.5-20 &#x3bc;g/100 cal of the nutritional composition. A pharmaceutical formulation, a nutritional formulation, a tube-feed formulation, a dietary supplement, a functional food, a beverage product or a combination thereof comprising the nutritional composition is also disclosed. A method for improving musculoskeletal health is also disclosed.

Nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease (IBD)

The present invention relates generally to the field of nutrition, more particularly to the use of probiotics in nutrition. In particular the present invention relates to the use of a probiotic or of a mixture of probiotics in the manufacture of a nutritional composition or a medicament to act the colon in a pre- or post surgical environment.

Probiotics in a pre- and/or post-surgical environment

A nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease is disclosed. The nutritional composition comprises casein protein, vitamin K in a ratio of vitamin K1:vitamin K2 being between 3:1 to 1:3 and the vitamin K providing between 3.5-20 &#x3bc;g/100 kcal of the nutritional composition, vitamin D and alpha-linolenic acid. A pharmaceutical formulation, a nutritional formulation, a tube-feed formulation, a dietary supplement, a functional food, a beverage product or a combination thereof comprising the nutritional composition is also disclosed. A method for improving musculoskeletal health is also disclosed.

A nutritional composition is proposed comprising a probiotic and milk fat globule membrane (MFGM) wherein the MFGM and the probiotics mutually potentiate their respective effects and promote complementary beneficial protective mechanisms that reflect physiological synergy. The nutritional composition can be an infant formula, infant cereals, baby food or health care nutritional product. The synergistic effect can include promoting immune maturation and/or immune education and/or reducing inflammation and/or treating or preventing disease or infections.

Infant formula with probiotics and milk fat globule membrane components

The present invention provides novel strains of probiotics for use in the gastrointestinal tract of a pet. The probiotics of the present invention are capable of fermenting starch to produce lactic acid and/or hydrogen peroxide anti-pathogenic metabolites. The present invention also provides a novel method for identifying the effectiveness of a pet probiotic in vitro. The method simulates the introduction of a probiotic candidate in the gastrointestinal tract of a pet and measures the anti-pathogenic effectiveness of the probiotic.

Probiotic strains for pets

Probiotics in a pre- and/or post surgical environment

The invention relates to an infant formula comprising a source of protein in an amount of not more than 2.0 g/100 kcal, a source of lipids, a source of carbohydrate and a probiotic wherein the probiotic is present in an amount equivalent to between 10and 10cfu/g of dry formula. The invention further extends to the use of such an infant formula to modulate the immune system of a neonatal infant to promote the development in the first few weeks of the life of the infant of a beneficial intestinal microbiota comparable with that found in breast fed babies as well as to promote the maturation of the immune system of a neonatal infant in the first few weeks of life.

Infant formula with probiotics

The present invention relates to novel lactic acid bacterial micro-organisms that have been isolated and selected for their probiotic potential and their use for the preparation of petfood compositions intended to improve the health of pets, and to compositions containing the same.

Probiotics for pet food applications

The present invention relates to a composition comprising prebiotic (prebiotic adjuvant) for decreasing inflammatory process by improving the homeostasis of non-specific immune parameters and of lymphocyte subpopulations. It also relates to the use of a prebiotic formulation in the manufacture of a medicament or a food or petfood composition for decreasing inflammatory process and/or abnormal activation of non-specific immune parameters, such as phagocytes.

Composition comprising a prebiotic for decreasing inflammatory process and abnormal activation of non-specific immune parameters

The invention relates to the use of at least one strain of lactic acid bacteria and/or bifidobacteria having hydrophobic surface properties, for the preparation of a composition intended for the prevention or the treatment of endotoxin mediated and/or associated disorders and human or pet food compositions prepared thereof.

Endotoxin binding by lactic acid bacteria and bifidobacteria

Growing community of inventors

Crissier, Switzerland

Eduardo Schiffrin